Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education.
Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.
The SARS-CoV-2 omicron variant has affected which of our COVID-19 treatment strategies are currently effective, with some expected to maintain their efficacy and some expected to lose their efficacy. In this episode, Arthur Kim, MD, discusses the effects of the SARS-CoV-2 omicron variant on many of the COVID-19 approved, authorized, and investigational treatment options, including:
Department of Medicine
Harvard Medical School
Director, Viral Hepatitis Clinic
Division of Infectious Diseases
Massachusetts General Hospital
This program has been made available online.
Expert faculty provide a comprehensive overview of current landscape of outpatient COVID-19 management strategies, from Clinical Care Options (CCO), Practicing Clinicians Exchange (PCE), and ProCE
Dr Jason Gallagher and Dr Emily Heil on COVID-19 antivirals for nonhospitalized patients and COVID-19 rebound, from Clinical Care Options (CCO)
Clinical Care Options (CCO) podcast with Dr Princy N. Kumar and Dr Paul E. Sax on key COVID-19 data from IDWeek 2022
Dr Gregory Huhn discusses new COVID-19 data from IDWeek 2022 on severe breakthrough infection risk and antiviral treatment, from Clinical Care Options (CCO)